Details of the Drug Combination

General Information of Drug Combination (ID: DCHKAU7)

Drug Combination Name
ABIRATERONE Ixabepilone
Indication
Disease Entry Status REF
Clear cell renal cell carcinoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C Ixabepilone   DM2OZ3G
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TK-10
Zero Interaction Potency (ZIP) Score: 2.61
Bliss Independence Score: 2.08
Loewe Additivity Score: 0.61
LHighest Single Agent (HSA) Score: 0.12

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of Ixabepilone
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Breast carcinoma N.A. Approved [4]
Ixabepilone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Stablizer [6]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Clear cell renal cell carcinoma DC4ZEC1 CAKI-1 Investigative [1]
Papillary renal cell carcinoma DCF80QB ACHN Investigative [1]
Breast adenocarcinoma DCXXM9C MDA-MB-468 Investigative [9]
Carcinoma DCQ96LH MCF7 Investigative [9]
Colon carcinoma DC4WZA1 KM12 Investigative [9]
Invasive ductal carcinoma DC9FWLL T-47D Investigative [9]
Adenocarcinoma DC43MZS HCC-2998 Investigative [10]
Lung adenocarcinoma DCOKC2R MDA-MB-231 Investigative [10]
Lung adenocarcinoma DCFMMAO EKVX Investigative [10]
Malignant melanoma DCM5ZTM LOX IMVI Investigative [10]
Minimally invasive lung adenocarcinoma DC4MYSJ NCI-H322M Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
4 Ixabepilone FDA Label
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
8 The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
10 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976